

Bod to launch low dose CBD schedule 3 product into the Australian market via SAS-B channel

- **New medicinal cannabis product to be launched under Bod's existing medicinal cannabis brand as MediCabilis™ and sold as Bod Bio-Absorb 100™**
- **Bod Bio-Absorb 100™ is a uniquely developed CBD product in a soft gel delivery format which is currently being utilised in Bod's phase II clinical trial on symptoms associated with insomnia**
- **Launch expected to occur in July through Australian prescription market (SAS-B) – Bod has been selling medicinal cannabis products through prescription channels since 2018**
- **Bod Bio-Absorb 100™ expands existing medicinal cannabis range with a new delivery format and complements current medicinal cannabis range**
- **Bod to benefit from new product sales and consumer feedback prior to a launch into the over-the-counter Australian pharmacy market**

Sydney, Australia – 23 June 2022: Cannabis focused drug development and product innovation company Bod Australia Limited ("Bod" or "the Company") (ASX: BOD) is pleased to advise that it will launch a new medicinal cannabis product to the Australian market in July, available to consumers through the Therapeutic Goods Administration's (TGA) Special Access Scheme Category B ("SAS-B").

The TGA's Schedule Access Scheme allows certain healthcare practitioners to access certain therapeutic goods including medicines, medical devices and biologicals that are not included in the Australian Register of Therapeutic Goods (ARTG) for a single patient. Bod has been consistently selling products through SAS-B channels since 2018 (refer ASX announcement: 25 October 2018) and has built a strong foothold in the market.

The new product will be launched under Bod's existing medicinal cannabis brand as MediCabilis™ and sold as Bod Bio-Absorb 100™. Bio-Absorb 100™ is made up of a uniquely developed CBD formulation in a soft gel delivery format and is currently being utilised in the Company's phase II clinical trial (refer ASX announcement: 10 May 2022). The launch will highlight the Company's fourth product available to Australian consumers through prescription channels. Upon successful completion of Bod's phase II clinical trial and other required regulatory approvals, Bio-Absorb 100™ will be sold over-the-counter through pharmacists.

The launch of Bod Bio-Absorb 100™ will expand Bod's existing medicinal cannabis range, introduce a new delivery format for consumers and complement the Company's existing products that are being used to alleviate a range of conditions including chronic pain, anxiety and insomnia amongst others.

To drive product awareness and uptake, the Company has engaged with a number of healthcare professionals and approved prescribers to further educate them on the benefits of Bod Bio-Absorb 100™. Bod will provide additional updates on the launch and product sales growth as it materialises.

CEO Ms Jo Patterson said: *"The launch of Bod Bio-Absorb 100™ provides Bod with another product in the Australian medicinal cannabis prescription market, which has the potential to increase sales and brand awareness. Importantly, the introduction of the product through prescription channels will also provide us with valuable feedback as we continue our clinical trial and endeavour to launch Bod Bio-Absorb 100™ through the Australian pharmacy market in the coming months."*

"We continue to make pleasing progress in our patient recruitment initiatives for our phase II clinical trial and look forward to providing additional updates to shareholders as these complete."

This announcement has been approved by the Board of Bod Australia Limited.

-ENDS-

CONTACT

T +61 2 9199 5018 E info@bodaustralia.com bodaustralia.com

About Bod Australia:

Bod Australia Limited (ASX:BOD) Bod is a cannabis focused drug development and product innovation company.

Bod is focused on progressing R&D and a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for the consumer and medical markets.

The company has a number of existing partnerships with large corporate groups and collaborations with leading research partners to advance the use of CBD.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538